Recent updates from the ASH 2025 conference highlight novel agents and evolving treatment strategies for Waldenström macroglobulinemia. These clinical trial results may inform future therapeutic approaches in managing this rare blood cancer.
novel agents and evolving strategies in waldenstr m macroglobulinemia clinical trial updates from ash 2025
Original title: “Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025.”